Claude Bertrand joins Ipsen as Chief Scientific Officer
pharmafile | October 27, 2009 | Appointment | Research and Development | appointment, ipsen, research and development
Ipsen has appointed Claude Bertrand (pictured) chief scientific officer and Jacques-Pierre Moreau chief scientific advisor.
Bertrand moves to the company next week, when he will become executive vice president, chief scientific officer and a member of the Ipsen Group’s executive committee.
He was most recently senior vice president at AstraZeneca R&D and his international research career spans over 20 years, starting with Ciba-Geigy (now Novartis) then Roche Bioscience (part of F. Hoffmann-La Roche Ltd) and Pfizer Global R&D.
In his new role he will lead Ipsen’s discovery and Innovation operations at Les Ulis (France), Milford (USA) and Barcelona (Spain) and will be jointly based in the company’s Paris/Boulogne and Milford sites.
At Ipsen Bertrand will succeed Jacques-Pierre Moreau, who will continue to contribute to the company’s future in an advisory position, as chief scientific advisor, to the executive committee on scientific, medical and technical matters.
In this non-executive position, he will perform strategic missions and participate to non-operational oversight of spin-offs, venture funding and academic alliances.
Jean-Luc Bélingard, chairman and chief executive of Ipsen, said: “In the changing environment of the pharmaceutical industry, it is more than ever imperative for Ipsen to remain at the forefront of drug discovery with first-in-class products as well as creative life cycle management programmes that foster closer links with health care providers and patients.
“We have to continue to creatively enrich our innovation pipeline, and at the same time bring to fruition as quickly as possible our current projects as they result from our long-term dedication to R&D, integral part of Ipsen’s DNA. With C. Bertrand at the helm of D&I and with the benefit of J-P. Moreau long-term experience and knowledge of the life sciences as applied to therapeutic R&D, I am convinced that our future as an innovation company is in good hands.”
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
